The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies (Q82953970)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 December 2010

Language	Label	Description	Also known as
English	The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies	scientific article published on 18 December 2010

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

based on heuristic

inferred from title

author name string

Peyman Hadji

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lina Asmar

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Johanna G H van Nes

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thomas Menschik

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Annette Hasenburg

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Joachim Kuck

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Johan W R Nortier

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Cornelis J H van de Velde

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Stephen E Jones

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

May Ziller

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

18 December 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

137

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1015-1025

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

https://scigraph.springernature.com/pub.10.1007/s00432-010-0964-y

0 references

Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical guidance for the management of aromatase inhibitor-associated bone loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of adult bone turnover by sex steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Menopausal symptoms and adjuvant therapy-associated adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-010-0964-Y

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170551%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82953970&oldid=1962120784"